{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-000005","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.921343+00:00","generated_at":"2026-05-28T18:11:25.952885+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option","bullets":["Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.","Base salary $450,000; discretionary annual bonus target up to 40% of base salary.","Received inducement stock option to purchase 150,000 shares, vesting over 4 years with 12-month cliff.","Severance includes 9 months base salary (12 months if termination within 6 months after Change in Control) and full option vesting.","Company advancing AVTX-009 (anti-IL-1β mAb) in LOTUS Phase 2 trial for hidradenitis suppurativa."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-000005","json":"https://secwatch.observer/filing/0001628280-25-000005.json","markdown":"https://secwatch.observer/filing/0001628280-25-000005.md","text":"https://secwatch.observer/filing/0001628280-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/0001628280-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/avtx-20250101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:11:25.952885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d91fdde4c","claim":"Jennifer Riley was appointed as Chief Strategy Officer at Avalo Therapeutics, Inc..","evidence_excerpt":"On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/0001628280-25-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}